Malignant Mesothelioma

Global Market Trajectory & Analytics

MCP13152

EXECUTIVE ENGAGEMENTS

POOL

6789
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

1086
Interactions with Platform & by Email

PARTICIPANTS

204
Unique # Participated

VALIDATIONS

92
Responses Validated*

COMPANIES

43
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

66

PAGES

139

EDITION

8

PRICE

USD 4950

CODE

MCP13152


COMPETITIVE METRICS

COMPANY

D S N T

% *

AstraZeneca PLC

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Company

Corden Pharma International GmbH

Eli Lilly and Company

F. Hoffmann-La Roche AG

Kyowa Kirin Co., Ltd.

Merck & Co., Inc.

MolMed SpA

Mylan NV

View More...

SUBMIT
Note: Best viewed in Landscape Mode
  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Malignant Mesothelioma estimated at US$379.2 Million in the year 2020, is projected to reach a revised size of US$574.6 Million by 2027, growing at a CAGR of 6.1% over the analysis period 2020-2027. Premetrexed and combination, one of the segments analyzed in the report, is projected to record a 6.7% CAGR and reach US$302.7 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Cisplatin and combination segment is readjusted to a revised 6% CAGR for the next 7-year period.
The Malignant Mesothelioma market in the U.S. is estimated at US$112 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$100.7 Million by the year 2027 trailing a CAGR of 5.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.8% and 4.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.
In the global Carboplatin and combination segment, USA, Canada, Japan, China and Europe will drive the 5.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$40.4 Million in the year 2020 will reach a projected size of US$59.8 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$65.9 Million by the year 2027.

SELECT PLAYERS

AstraZeneca PLC; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Concordia International Corporation; Corden Pharma International GmbH; Eli Lilly and Company; F. Hoffmann-La Roche AG; Fresenius Kabi AG; Kyowa Hakko Kirin Co., Ltd.; Merck & Co., Inc.; MolMed S.p.A.; Mylan NV; Nichi-Iko Pharmaceutical Co., Ltd.; Novartis International AG; Ono Pharmaceutical Co., Ltd.; Pfizer, Inc.; Polaris Pharmaceuticals, Inc.; Sanofi S.A.; Sun Pharmaceutical Industries Ltd.; Teva Pharmaceutical Industries Ltd.

SEGMENTS

» Drug Class (Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination, Other Combinations)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Malignant Mesothelioma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Malignant Mesothelioma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Malignant Mesothelioma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for Premetrexed and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Premetrexed and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Premetrexed and combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Cisplatin and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Cisplatin and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Cisplatin and combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Carboplatin and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Carboplatin and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Carboplatin and combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Gemcitabine and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Gemcitabine and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Gemcitabine and combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Vinorelbine and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Vinorelbine and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Vinorelbine and combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Other Combinations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Other Combinations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Combinations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027
CANADA
Canada Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027
JAPAN
Japan Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027
CHINA
China Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027
EUROPE
Europe Current & Future Analysis for Malignant Mesothelioma by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Europe Historic Review for Malignant Mesothelioma by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Malignant Mesothelioma by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027
GERMANY
Germany Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027
ITALY
Italy Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027
Total Companies Profiled: 43

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com